

FUCHS HENRY J
Form 4
February 26, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
FUCHS HENRY J

2. Issuer Name and Ticker or Trading Symbol
GENOMIC HEALTH INC [GHDX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE

3. Date of Earliest Transaction (Month/Day/Year)
02/22/2019

Director 10% Owner
 Officer (give title below) Other (specify below)

(Street)

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

NOVATO, CA 94949

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Stock	02/22/2019		M		20,000 A \$ 33.67	26,332	D
Common Stock	02/22/2019		M		6,479 A \$ 27.75	32,811	D
Common Stock	02/22/2019		S		11,479 D \$ 82.1127	21,332	D
					(1) (2)		
Common Stock	02/22/2019		S		14,490 D \$ 81.7037	6,842	D
					(1) (3)		
	02/22/2019		S		510 D	6,332	D

Edgar Filing: FUCHS HENRY J - Form 4

Common Stock						\$		
						82.2454		
						<u>(1) (4)</u>		
Common Stock	02/25/2019		M	3,521	A	\$ 27.75	9,853	D
Common Stock	02/25/2019		S	3,000	D	\$ 78.8833	6,853	D
						<u>(1) (5)</u>		
Common Stock	02/25/2019		S	521	D	\$ 79.8014	6,332	D
						<u>(1) (6)</u>		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Director Stock Option (right to buy)	\$ 33.67	02/22/2019		M	20,000	<u>(7)</u> 09/17/2023	Common Stock 20,000
Director Stock Option (right to buy)	\$ 27.75	02/22/2019		M	6,479	06/06/2015 06/06/2024	Common Stock 6,479
Director Stock Option (right to buy)	\$ 27.75	02/25/2019		M	3,521	06/06/2015 06/06/2024	Common Stock 3,521

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FUCHS HENRY J BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	X			

Signatures

/s/ Jason W. Radford, Attorney-in-fact	02/26/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
 - (2) Represents weighted average sale price. Actual sale prices ranged from \$82.00 to \$82.34.
 - (3) Represents weighted average sale price. Actual sale prices ranged from \$81.21 to \$82.20.
 - (4) Represents weighted average sale price. Actual sale prices ranged from \$82.21 to \$82.2538.
 - (5) Represents weighted average sale price. Actual sale prices ranged from \$78.50 to \$79.17.
 - (6) Represents weighted average sale price. Actual sale prices ranged from \$79.54 to \$80.02.
 - (7) The option became exercisable as to 25% of the shares on September 17, 2014, and became exercisable as to 1/48th of the shares each full month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.